Accessibility Menu
Syros Pharmaceuticals logo

Syros Pharmaceuticals(OTC) SYRS

Current Price$0.00
Market Cap$5.40KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2016)-100%
5 Year-100%
1 Year-98%
1 Month+100%
Syros Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 0.002026-07-20
Syros Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+100%USD 0.002026-07-13
1 month+100%USD 0.002026-06-18
3 month+0%USD 0.002026-04-21
Year to date-42.86%USD 0.002025-12-31
1 year-98%USD 0.012025-07-18
3 year-99.99%USD 3.502023-07-21
5 year-100%USD 50.302021-07-21
Since inception-100%USD 181.502016-06-30

Syros Pharmaceuticals Financials at a Glance

Market Cap

$5.40KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$386.00K

Net Income (TTM)

-$97.82M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

8.14 (High)

Price

$0.00

Volume

1,977

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.03

Estimated Earnings Date

Jul 29, 2026

SYRS News

rising_stock_chart_lcd_screen

Why Syros Pharmaceuticals Stock Is Soaring Today

Keith SpeightsDec 20, 2019
ibms-global-center-for-watson-iot-in-munich-germanyjpg-4

Why IBM, Extraction Oil & Gas, and Syros Pharmaceuticals Slumped Today

Dan CaplingerOct 17, 2019
paper airplane down

Here's Why Syros Pharmaceuticals Is Collapsing Today

Maxx ChatskoApr 5, 2019
123 stock down man looking getty

Here's Why Syros Pharmaceuticals Got Crushed Today

Maxx ChatskoDec 11, 2017

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing treatments for hematologic malignancies, such as higher-risk myelodysplastic syndrome (HR-MDS) and acute myeloid leukemia (AML). They are invested in advancing therapies that target gene control mechanisms to offer new solutions for patients with challenging blood disorders.

Products and Services

Tamibarotene: A selective retinoic acid receptor alpha (RAR) agonist in clinical trials for HR-MDS and AML.

Syros is currently collaborating with Qiagen to develop and commercialize a companion diagnostic test for patient selection in trials.

Continuing development of additional clinical programs in partnership with other industry players.

What Makes Syros Pharmaceuticals, Inc. Special

Unlike traditional treatments that merely target genetic mutations, Syros Pharmaceuticals leverages its unique platform to modulate gene expression. By focusing on gene control rather than genetic mutations alone, Syros stands at the forefront of innovative cancer treatment approaches, particularly for blood-related disorders.

Five Things You Need to Know

Syros's lead product, Tamibarotene, is in late-stage trials for HR-MDS and AML.

The company’s strategy is backed by a proprietary platform focused on gene regulatory elements.

Syros has secured FDA Fast Track Designation for Tamibarotene in specific patient populations, speeding up the review process.

Syros's leadership team possesses extensive experience in biotechnology and pharmaceuticals, aligning with its strategic growth vision.

The company has made strategic partnerships, notably with Qiagen, to enhance its diagnostic capabilities alongside therapeutic developments.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

68

CEO

Conley Chee, MBA; Nancy A. Simonian, MD

Website

www.syros.com

Headquarters

Cambridge, MA 02140, US

SYRS Financials

Key Financial Metrics (TTM)

Gross Margin

77.33%

Operating Margin

-1298.19%

Net Income Margin

-1656.34%

Return on Equity

-227.94%

Return on Capital

-163.82%

Return on Assets

-97.86%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$5.40KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

26.83M

Volume

1.98K

Avg. Volume

11.97K

Financials (TTM)

Gross Profit

-$883.00K

Operating Income

-$111.52M

EBITDA

-$91.22M

Operating Cash Flow

-$100.02M

Capital Expenditure

-$38.00K

Free Cash Flow

-$100.06M

Cash & ST Invst.

$58.28M

Total Debt

$60.23M

Syros Pharmaceuticals Performance Analysis

Syros Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 23,488,000N/A
20222022-12-31USD 14,880,000-36.6%
20232023-12-31USD 9,936,000-33.2%
Syros Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42023-12-31-89.7%
Q12024-03-31-100.0%
Q22024-06-30N/A
Q32024-09-30N/A
Syros Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -13.84N/A
20222022-12-31USD -7.49-45.9%
20232023-12-31USD -5.81-22.5%
Syros Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42023-12-31-52.4%
Q12024-03-3195.6%
Q22024-06-30-520.4%
Q32024-09-3072.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2024YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

-$325.00K

-110.3%

Gross Margin

0.00%

N/A

Market Cap

$5.40KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$79.41

N/A

Employees

68

N/A

Net Income

-$6.40M

+84.1%

EBITDA

-$4.76M

+87.5%

Quarterly Fundamentals

Name
Q3 2024YOY CHG

Total Cash

$58.28M

-48.1%

Total Debt

$60.23M

-6.9%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$57.64M

-1.6%

Short Term Debt

$2.58M

-58.0%

Return on Assets

-97.86%

N/A

Return on Invested Capital

-98.09%

N/A

Free Cash Flow

-$20.69M

+35.1%

Operating Cash Flow

-$20.69M

+35.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
VRPXVirpax Pharmaceuticals, Inc.
$0.00-96.40%
SLXNWSilexion Therapeutics Ltd.
$0.05+0.00%
VINCVincerx Pharma, Inc.
$0.01-15.89%
PPBTPurple Biotech Ltd.
$1.42-2.08%

Trending Stocks

Symbol / CompanyPricePrice Chg
UTZUtz Brands
$14.12+0.89%
JOBYJoby Aviation
$7.70+0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$11.39+0.06%
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$35.01+0.24%

Questions About SYRS

What is the current price of Syros Pharmaceuticals?

Syros Pharmaceuticals is trading at $0.00 per share.

What is the 52-week range for Syros Pharmaceuticals?

Over the past 52 weeks, Syros Pharmaceuticals has traded between $0.00 and $0.03.

How much debt does Syros Pharmaceuticals have?

As of the most recent reporting period, Syros Pharmaceuticals reported total debt of $60.23M.

How much cash does Syros Pharmaceuticals have on hand?

Syros Pharmaceuticals reported $58.28M in cash and cash equivalents in its most recent financial results.

What is Syros Pharmaceuticals’s dividend yield?

Syros Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services